Kasamatsu A.Miyahara R.Yoneoka D.Toyo-oka L.Chiyasirinroje B.Imsanguan W.Suvichapanich S.Yanai H.Wattnapokayakit S.Nedsuwan S.Boonbangyang M.Palittapongarnpim P.Tokunaga K.Mushiroda T.Mahasirimongkol S.Mahidol University2025-04-282025-04-282025-06-01International Journal of Infectious Diseases Vol.155 (2025)12019712https://repository.li.mahidol.ac.th/handle/123456789/109798Background: NAT2 polymorphisms affect isoniazid metabolism, but their effect on mortality among individuals with tuberculosis (TB) remains unclear. Methods: This study used data from two TB cohorts (2005–2011, 2014–2020) and death certificate records in Thailand. Newly diagnosed Thai individuals treated with isoniazid-containing regimens were included. NAT2 genotypes—rapid, intermediate, and slow acetylator (RA, IA, SA)—were classified via haplotype inference. The primary outcome was 1-year all-cause mortality, while secondary outcomes included TB-related mortality, TB+respiratory disease-related mortality recorded in the vital registration system, and death as a TB treatment outcome. Adjusted hazard ratios (aHRs) relative to the IA type were estimated using stratified Cox proportional hazards models. Subgroup analyses targeted individuals with isoniazid-resistant TB and HIV infection. Results: A total of 1,065 individuals (766 males; mean age=51 years) were analyzed. Individuals with RA had a 1.70-fold greater all-cause mortality risk (95 % CI: 1.03–2.80) than IA. The aHRs for RA were 1.14 (0.43–3.03) for TB-related mortality, 1.59 (0.80–3.18) for TB+respiratory disease-related mortality, and 1.26 (0.67–2.37) for TB treatment outcome death. Among individuals with isoniazid-resistant TB, those with RA had a 4.68-fold (1.14–19.12) greater aHR for all-cause mortality. Conclusion: The RA type is associated with increased 1-year all-cause mortality.MedicineArticleSCOPUS10.1016/j.ijid.2025.1078952-s2.0-1050028608401878351140147587